Momelotinib is currently in clinical development for the treatment of symptomatic myelofibrosis
with anaemia. Myelofibrosis is a rare blood cancer, where the bone marrow is too active so scar
tissue builds up inside the bone marrow and blood cells cannot develop properly. The reduction
in blood cells can result in anaemia, amongst other symptoms such as tiredness, shortness of
breath and easily bleeding and bruising.
Momelotinib for the treatment of symptomatic and anaemic myelofibrosis
Momelotinib is currently in clinical development for the treatment of symptomatic myelofibrosis with anaemia
Interventions:
Momelotinib
Indications:
Anaemic myelofibrosis
Year:
2022